Gary Brecka on Longevity: What He Has Said About Medication

Who Is Gary Brecka and Why Does His Medication Stance Matter?

Gary Brecka describes himself as a human biologist and spent roughly two decades as a mortality analyst projecting life expectancy for life-insurance companies. He co-founded 10X Health System alongside Gabrielle Abi-Esber, offering blood-panel analysis, genetic testing, and supplement protocols. His profile rose sharply after a 2023 appearance on the Joe Rogan Experience (episode 1950), where he reached an audience of tens of millions.

His medication opinions matter clinically because a large number of people are making real health decisions based on his advice. Understanding precisely what he said, where his claims align with peer-reviewed data, and where they do not, is a genuine public-health question.

His Professional Background

Brecka has stated in multiple interviews that his actuarial work involved correlating blood biomarkers with death dates. He claims this work showed him that nutrient deficiencies predicted mortality more reliably than pharmaceutical intervention corrected it. These claims are not peer-reviewed. No published study from Brecka or 10X Health appears in PubMed as of early 2025.

The 10X Health Platform

10X Health sells genetic testing kits, IV nutrient therapy packages, and targeted supplement stacks. The company operates in the same commercial space as functional medicine clinics. The Federal Trade Commission has published guidance noting that testimonial-heavy health marketing must be substantiated by competent scientific evidence, a standard Brecka's public claims have not yet been subjected to in a formal regulatory proceeding.

What Gary Brecka Has Publicly Said About Pharmaceutical Medication

Brecka's medication statements are spread across podcast interviews, his own podcast "The Ultimate Human," and social media. His position is not uniformly anti-medication. It is more specifically anti-symptom-suppression without root-cause correction.

"Drugs Treat Deficiency With Deficiency"

In a widely circulated 2023 interview, Brecka stated: "We are not sick because we have a drug deficiency. We are sick because we have a nutrient deficiency." He has repeated this framing consistently, including on The Diary of a CEO with Steven Bartlett.

This framing has partial scientific support in specific contexts. Iron-deficiency anemia, for example, is genuinely caused by a nutrient deficit, and oral iron supplementation (325 mg ferrous sulfate daily) is first-line therapy per American Society of Hematology guidance rather than pharmaceutical intervention [1]. Scurvy is vitamin C deficiency. Pellagra is niacin deficiency. These cases support the concept. The extension of that concept to conditions like hypertension, type 2 diabetes, or major depressive disorder, however, is not supported by the same weight of evidence.

His Stance on Statins

Brecka has publicly questioned statin therapy on multiple platforms, arguing that lowering LDL cholesterol without addressing inflammation and nutrient status does not produce the predicted survival benefit for all patients. He specifically references CoQ10 depletion as a mechanism of harm.

The clinical literature here is nuanced. Statins do inhibit the mevalonate pathway, which reduces both cholesterol synthesis and CoQ10 synthesis [2]. The JUPITER trial (N=17,802) showed rosuvastatin 20 mg reduced major cardiovascular events by 44% versus placebo in patients with elevated hsCRP and normal LDL [3]. Statin benefit is well-established in secondary prevention; the evidence is somewhat weaker in primary prevention for low-risk individuals, which is the patient population Brecka most often appears to be addressing. Brecka's concern about CoQ10 is physiologically real, though the clinical significance of statin-induced CoQ10 reduction remains debated in the literature [4].

His Stance on Antidepressants

Brecka has stated that serotonin deficiency as the root cause of depression is an "outdated hypothesis" and that many antidepressants are therefore addressing the wrong target. He advocates instead for correcting methylation defects, B12, and folate status.

A 2022 umbrella review in Molecular Psychiatry (Moncrieff et al.) examined the serotonin-depression hypothesis across multiple study types and concluded that existing evidence does not support a direct relationship between serotonin levels or activity and depression [5]. This review was controversial; several psychiatrists published rebuttals arguing the serotonin model was a simplification that had already been abandoned in academic psychiatry. SSRIs retain strong evidence for moderate-to-severe major depressive disorder, with meta-analyses supporting a number-needed-to-treat of approximately 7 for response [6]. Brecka's critique aligns with the academic debate but does not reflect the full clinical picture for patients with moderate or severe symptoms.

MTHFR, Methylation, and Brecka's Core Protocol

The center of Brecka's public health framework is the MTHFR gene. He argues that a large percentage of the population carries variants that impair folate metabolism, leading to elevated homocysteine, impaired neurotransmitter synthesis, and a cascade of downstream health problems.

What MTHFR Actually Does

The MTHFR gene encodes methylenetetrahydrofolate reductase, an enzyme that converts folate into its active form (5-methyltetrahydrofolate, or 5-MTHF). The C677T variant reduces enzyme activity by approximately 35% in heterozygotes and 70% in homozygotes [7]. The A1298C variant produces a smaller reduction. Together, these are among the most common genetic variants in humans, with the C677T homozygous genotype present in roughly 10% of most populations studied [7].

Brecka's claim that this variant is responsible for a broad range of psychiatric and physical conditions is extrapolated beyond what the research currently supports. The variant is associated with modestly elevated homocysteine. Elevated homocysteine is associated with increased cardiovascular risk [8]. The causal chain from MTHFR variant to clinical disease is longer and less direct than Brecka typically presents it.

The Supplement Protocol He Describes

Brecka recommends bypassing the impaired enzyme by supplementing directly with L-5-MTHF (methyl-folate) and methylcobalamin (methyl-B12) rather than folic acid or cyanocobalamin, which require MTHFR activity to convert into usable forms. This recommendation has a legitimate biochemical rationale. A 2017 review in Nutrients confirmed that L-5-MTHF is bioavailable independent of MTHFR genotype and may be preferable for individuals with confirmed variants [9]. The clinical question is whether supplementing these nutrients in people with variants who are otherwise healthy produces measurable health improvements. Large RCT data on that specific question are limited.

What He Has Said He Personally Takes

In the Joe Rogan interview and on his own podcast, Brecka has described his personal protocol as including methylated B vitamins, magnesium (he has cited magnesium glycinate specifically), omega-3 fatty acids, and vitamin D3 with K2. He has not publicly disclosed use of prescription pharmaceuticals for chronic conditions. He has expressed interest in peptide therapy and has discussed BPC-157 and other peptides in a favorable context on his podcast, though he frames these as research-stage compounds rather than established medical treatments.

The table below summarizes Brecka's stated protocol elements against the available clinical evidence grade.

| Protocol Element | Brecka's Stated Rationale | Evidence Grade (per NIH ODS) | |---|---|---| | L-5-MTHF | Bypasses MTHFR impairment | Moderate (homocysteine lowering confirmed) | | Methylcobalamin | Active B12 form; supports methylation | Moderate | | Magnesium glycinate | Cofactor in 300+ enzymatic reactions | Moderate-High for deficiency states | | Vitamin D3 + K2 | Immune, bone, cardiovascular support | Moderate (D3); Limited (K2 combo) | | Omega-3 (EPA/DHA) | Reduce inflammatory markers | High (cardiovascular outcomes) | | BPC-157 | Tissue repair; gut healing | Low (animal studies only as of 2025) | | Grounding / earthing | Reduce oxidative stress | Very Low (small pilot studies only) |

Gary Brecka on Hormone Optimization

Brecka has spoken favorably about testosterone replacement therapy (TRT) and broader hormone optimization in men. He frames low testosterone not as an inevitable feature of aging but as a correctable deficiency, consistent with the nutrient-deficiency framing he applies elsewhere.

His Public Statements on TRT

On episode 1950 of the Joe Rogan Experience, Brecka discussed testosterone optimization as a legitimate medical intervention when levels are genuinely low, distinguishing this from performance enhancement. He has stated that free testosterone is the more clinically meaningful marker than total testosterone, an assertion that has support in some clinical contexts. A 2021 analysis in the Journal of Clinical Endocrinology and Metabolism found that free testosterone calculated by the Vermeulen equation better predicted hypogonadal symptoms than total testosterone in a cohort of 1,489 men [10].

What the TRT Evidence Shows

The Testosterone Trials (TTrials, N=790 men aged 65 and older) showed that testosterone treatment for 12 months improved sexual function, physical function measured by walking distance, and bone density compared to placebo [11]. The cardiovascular signal from TRT remains an active area of study. The TRAVERSE trial (N=5,246, published 2023 in NEJM) found that testosterone replacement was non-inferior to placebo for major adverse cardiovascular events in men with hypogonadism and elevated cardiovascular risk, with a hazard ratio of 0.96 (95% CI 0.78 to 1.17) [12]. Brecka's favorable framing of TRT is consistent with current evidence in men with confirmed hypogonadism.

Where Brecka's Claims Diverge From Clinical Consensus

Not all of Brecka's public statements sit comfortably with established medicine. Several deserve specific scrutiny.

The Lifespan Prediction Claim

Brecka has stated in multiple interviews that, based on bloodwork alone, he can predict a person's death to within six months. No peer-reviewed methodology supports this level of precision from standard biomarkers. The most validated biological age clocks (Horvath DNAm clock, PhenoAge, GrimAge) produce hazard-ratio estimates for mortality risk, not individual death dates with months-level precision [13]. This claim should be treated as marketing language rather than clinical fact.

Dismissal of Vaccines and Some Preventive Pharmaceuticals

Brecka has made statements on social media and podcasts expressing skepticism about certain vaccines and standard pharmaceutical preventive interventions. These statements are not documented here in detail because the specific claims shift across platforms. Readers are directed to CDC and WHO guidance for vaccine recommendations, which are based on population-level efficacy and safety data that are not undermined by the nutrient-status arguments Brecka advances [14].

The Breathwork and Grounding Claims

Brecka is an advocate for specific breathwork protocols (citing Wim Hof-style methods) and grounding, defined as direct physical contact with the Earth's surface. On breathwork, a 2023 RCT in Cell Reports Medicine (N=114) found that cyclic sighing (a specific breathwork pattern practiced five minutes daily) significantly reduced self-reported anxiety and improved positive affect compared to mindfulness meditation and box breathing over four weeks [15]. This is genuine supporting evidence for a component of Brecka's recommendations. Grounding has far thinner evidence; a 2015 pilot study in the Journal of Inflammation Research found reduced inflammatory markers in 12 subjects after grounding, but the sample size precludes conclusions [16].

How to Evaluate Brecka's Approach as a Patient

Patients encounter Brecka's content through social media algorithms, not medical referrals. The content is polished, confident, and often superficially consistent with real biochemistry. A few clinical principles help separate signal from noise.

Distinguishing Association From Causation

Many of Brecka's claims rest on nutrient-disease associations that are real but do not yet have RCT-level causal proof. Low vitamin D is associated with worse COVID-19 outcomes in observational data, but supplementation trials have produced mixed results [17]. The association is worth knowing; the causal mechanism is not settled. Patients should ask their clinician which of their specific health concerns have nutrient-deficiency RCT evidence and which are association-based.

Getting Tested Before Supplementing

Brecka consistently recommends testing before treating, which is clinically sound. The NIH Office of Dietary Supplements notes that fat-soluble vitamins (A, D, E, K) can accumulate to toxic levels with unsupervised supplementation [18]. Anyone following Brecka-inspired protocols should obtain baseline 25-OH vitamin D, B12, folate, homocysteine, CBC, and a comprehensive metabolic panel before starting high-dose regimens.

When Pharmaceuticals Remain Necessary

A physician reviewing Brecka's framework would note that some conditions have pharmaceutical treatments where no nutrient intervention has shown equivalent efficacy. Type 1 diabetes requires insulin. Severe hypertension above 180/120 mmHg requires antihypertensive medication. Active bacterial infections require antibiotics. A 2023 AHA/ACC guideline update on hypertension management retained pharmacotherapy as first-line for Stage 2 hypertension (systolic above 140 mmHg in high-risk patients), alongside lifestyle change [19]. No supplement protocol has been shown to match antihypertensive drug efficacy in that population.

What Physicians Say About the Brecka Phenomenon

The functional medicine and conventional medicine communities have had public disagreements about Brecka's work. The criticism from academic physicians tends to focus on the precision of his claims rather than a wholesale dismissal of nutrient optimization.

Peter Attia, MD, who also runs a high-profile longevity practice, has said in his podcast and writing that MTHFR testing has limited clinical utility in the absence of elevated homocysteine, a position consistent with American College of Medical Genetics guidance, which states that population-based MTHFR screening is not recommended [20]. This represents a direct methodological disagreement with Brecka's core commercial offering.

Rhonda Patrick, PhD, has discussed MTHFR and methylation extensively and generally agrees that methylated B-vitamin forms are preferable for carriers of the C677T variant, but she frames the magnitude of benefit more conservatively than Brecka typically does.

The American College of Medical Genetics and Genomics 2013 statement concluded: "MTHFR polymorphism testing is not useful for the assessment of cardiovascular disease risk or for directing B-vitamin therapy" [20]. This guideline has not been superseded as of early 2025.